BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...

Alembic has received permission from the Food and Drug Administration for brexpiprazole tablets, which is the generic of Otsuka’s Rexulti. Brexpiprazole is an atypical antipsychotic used as an ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company with a market capitalization of $5.2 billion focused on developing novel therapies for central nervous system (CNS) disorders, has ...

The FDA approved 16 psychiatric drugs over the last decade, most of which shared similar mechanisms of action with previously ...

In the AD agitation market, AXS-05 is expected to compete with brexpiprazole, the only FDA-approved treatment for this indication. However, AXS-05's potentially superior safety profile ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company has been gaining significant ...

Key highlights Lundbeck's total revenue grew by +14% CER[1] (+11% DKK) to DKK 22,004 million in 2024, with all regions contributing to growth United States: DKK 11,325 million (+16% CER; +15% DKK) Eur ...

Rexulti (brexpiprazole) has potential interactions with alcohol and other medications. For example, Rexulti can interact with other antipsychotics, such as risperidone (Risperdal). An interaction ...

Rexulti (brexpiprazole) is already one of the two drugmakers’ fastest-growing products, and analysts have suggested that the new use could swell sales by $500 million to $1 billion, which would ...

Alembic Pharmaceuticals (Alembic) announced that it has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Brexpiprazole Tablets ...

Alembic Pharmaceuticals announced that it has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Brexpiprazole Tablets.

Brexpiprazole is an atypical antipsychotic used as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults, and also used in treatment of schizophrenia ...